OBJECTIVE: To estimate the incidence and prevalence of cytomegalovirus retinitis (CMV-R) in late-stage human immunodeficiency virus type 1 disease. DESIGN: Cohort study. SETTING: The Multicenter AIDS Cohort Study, an ongoing 10-year study of human immunodeficiency virus type 1-infected homosexual men with semiannual visits and CD4+ cell testing. STUDY PARTICIPANTS: Three hundred sixty-seven human immunodeficiency virus type 1-infected men from the Multicenter AIDS Cohort Study who were receiving zidovudine and Pneumocystis carinii prophylaxis and who had CD4+ cell counts fall below 0.10 x 10(9)/L (100/microL). MAIN OUTCOME MEASURES: Kaplan-Meier-type estimates for various longitudinal quantifications of incidence and prevalence of CMV-R were obtained. RESULTS: Among these 367 individuals, cytomegalovirus disease developed in 103, of whom 73 (71%) had ocular complications. At 4 years after the first CD4 cell count ( < 0.10 x 10(9)/L), the probability for these subjects to have (1) remained living without CMV-R was 11%, (2) died without experiencing CMV-R was 66%, (3) experienced CMV-R and be living was 6%, and (4) experienced CMV-R and died was 18%. During these 4 years, there was a 25% chance for the development of CMV-R and, on average, 0.211 person-years of CMV-R morbidity. Among those subjects in whom CMV-R developed, about 19% did have CMV-R before a CD4+ cell count of less than 0.05 x 10(9)/L ( < 50/microL) was observed, and 81% had CMV-R after the CD4+ cell count reached this threshold. CONCLUSION: These estimates may be relevant to current clinical practice and help in allocating resources and planning for treatment and prophylaxis against cytomegalovirus disease.
OBJECTIVE: To estimate the incidence and prevalence of cytomegalovirus retinitis (CMV-R) in late-stage human immunodeficiency virus type 1 disease. DESIGN: Cohort study. SETTING: The Multicenter AIDS Cohort Study, an ongoing 10-year study of human immunodeficiency virus type 1-infected homosexual men with semiannual visits and CD4+ cell testing. STUDY PARTICIPANTS: Three hundred sixty-seven human immunodeficiency virus type 1-infectedmen from the Multicenter AIDS Cohort Study who were receiving zidovudine and Pneumocystis carinii prophylaxis and who had CD4+ cell counts fall below 0.10 x 10(9)/L (100/microL). MAIN OUTCOME MEASURES: Kaplan-Meier-type estimates for various longitudinal quantifications of incidence and prevalence of CMV-R were obtained. RESULTS: Among these 367 individuals, cytomegalovirus disease developed in 103, of whom 73 (71%) had ocular complications. At 4 years after the first CD4 cell count ( < 0.10 x 10(9)/L), the probability for these subjects to have (1) remained living without CMV-R was 11%, (2) died without experiencing CMV-R was 66%, (3) experienced CMV-R and be living was 6%, and (4) experienced CMV-R and died was 18%. During these 4 years, there was a 25% chance for the development of CMV-R and, on average, 0.211 person-years of CMV-R morbidity. Among those subjects in whom CMV-R developed, about 19% did have CMV-R before a CD4+ cell count of less than 0.05 x 10(9)/L ( < 50/microL) was observed, and 81% had CMV-R after the CD4+ cell count reached this threshold. CONCLUSION: These estimates may be relevant to current clinical practice and help in allocating resources and planning for treatment and prophylaxis against cytomegalovirus disease.
Authors: Jens-Uwe Vogel; Jürgen Otte; Frank Koch; Hermann Gümbel; Hans Wilhelm Doerr; Jindrich Cinatl Journal: Med Microbiol Immunol Date: 2012-06-06 Impact factor: 3.402
Authors: Roland R Regoes; E Frances Bowen; Alethea V Cope; Dehila Gor; Aycan F Hassan-Walker; H Grant Prentice; Margaret A Johnson; Paul Sweny; Andrew K Burroughs; Paul D Griffiths; Sebastian Bonhoeffer; Vincent C Emery Journal: Proc Biol Sci Date: 2006-08-07 Impact factor: 5.349
Authors: Elizabeth A Sugar; Douglas A Jabs; Alka Ahuja; Jennifer E Thorne; Ronald P Danis; Curtis L Meinert Journal: Am J Ophthalmol Date: 2012-02-04 Impact factor: 5.258
Authors: Douglas A Jabs; Alka Ahuja; Mark Van Natta; Alice Lyon; Sunil Srivastava; Sapna Gangaputra Journal: Ophthalmology Date: 2010-07-29 Impact factor: 12.079
Authors: N A V Beare; J G Kublin; D K Lewis; M J Schijffelen; R P H Peters; G Joaki; J Kumwenda; E E Zijlstra Journal: Br J Ophthalmol Date: 2002-10 Impact factor: 4.638
Authors: Richard G Lalonde; Guy Boivin; Jean Deschênes; William G Hodge; J Jill Hopkins; Alex H Klein; Janette I Lindley; Peter Phillips; Stephen D Shafran; Sharon Walmsley Journal: Can J Infect Dis Med Microbiol Date: 2004-11 Impact factor: 2.471